Janice M. Reichert
#151,287
Most Influential Person Now
Researcher
Janice M. Reichert's AcademicInfluence.com Rankings
Janice M. Reichertengineering Degrees
Engineering
#6120
World Rank
#7425
Historical Rank
Electrical Engineering
#1780
World Rank
#1879
Historical Rank
Janice M. Reichertcomputer-science Degrees
Computer Science
#7981
World Rank
#8398
Historical Rank
Computational Linguistics
#1697
World Rank
#1715
Historical Rank
Machine Learning
#3135
World Rank
#3174
Historical Rank
Artificial Intelligence
#3437
World Rank
#3487
Historical Rank
Download Badge
Engineering Computer Science
Janice M. Reichert's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Janice M. Reichert Influential?
(Suggest an Edit or Addition)Janice M. Reichert's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Development trends for human monoclonal antibody therapeutics (2010) (909)
- Monoclonal antibody successes in the clinic (2005) (730)
- Future directions for peptide therapeutics development. (2013) (580)
- Bispecific antibodies: a mechanistic review of the pipeline (2019) (567)
- Development trends for monoclonal antibody cancer therapeutics (2007) (394)
- Marketed therapeutic antibodies compendium (2012) (386)
- Antibodies to watch in 2019 (2018) (369)
- Recombinant protein therapeutics—success rates, market trends and values to 2010 (2004) (331)
- Antibodies to watch in 2020 (2019) (318)
- Development trends for therapeutic antibody fragments (2009) (281)
- Antibody-based therapeutics to watch in 2011 (2011) (249)
- Monoclonal antibodies as innovative therapeutics. (2008) (243)
- Antibodies to watch in 2017 (2016) (242)
- A guide to drug discovery: Trends in development and approval times for new therapeutics in the United States (2003) (240)
- Antibodies to watch in 2018 (2018) (231)
- Antibodies to watch in 2021 (2021) (181)
- Antibodies to watch in 2016 (2016) (179)
- Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies (2011) (165)
- Clinical Approval Success Rates for Investigational Cancer Drugs (2013) (164)
- Monoclonal antibodies in the clinic (2001) (163)
- Antibodies to watch in 2015 (2015) (154)
- Which are the antibodies to watch in 2013? (2013) (143)
- Handbook of therapeutic antibodies (2007) (134)
- Development trends for new cancer therapeutics and vaccines. (2008) (130)
- Approval of the first biosimilar antibodies in Europe (2013) (128)
- Marketing approval of mogamulizumab (2012) (125)
- Antibodies to watch in 2022 (2022) (121)
- The future of antibodies as cancer drugs. (2012) (121)
- Monoclonal antibodies market (2004) (119)
- Antibody-drug conjugates (2013) (107)
- Antibodies to watch in 2010 (2010) (91)
- Antibodies to watch in 2014 (2014) (78)
- COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19 (2020) (77)
- Metrics for antibody therapeutics development (2010) (75)
- Which are the antibodies to watch in 2012? (2012) (71)
- Anti-infective monoclonal antibodies: perils and promise of development (2006) (60)
- European Medicines Agency workshop on biosimilar monoclonal antibodies (2009) (56)
- New biopharmaceuticals in the USA: trends in development and marketing approvals 1995-1999. (2000) (55)
- Antibodies to watch in 2014 (2014) (54)
- Therapeutic monoclonal antibodies: trends in development and approval in the US. (2002) (53)
- Antibodies to watch in 2013 (2013) (50)
- Total Syntheses of (+)-Acutiphycin and (+)-trans-20,21-Didehydroacutiphycin (1995) (49)
- World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA (2012) (48)
- Current trends in the clinical development of peptide therapeutics. (2009) (44)
- Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. (2003) (42)
- Trends in US approvals: new biopharmaceuticals and vaccines (2006) (35)
- Next generation and biosimilar monoclonal antibodies: Essential considerations towards regulatory acceptance in Europe; February 3-4, 2011; Freiburg, Germany (2011) (33)
- Public and private sector contributions to the discovery and development of "impact" drugs. (2002) (31)
- Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 – April 1, 2016, Tours, France (2016) (31)
- mAb therapeutic products and risk management (2010) (26)
- Antibody Fc: Linking Adaptive and Innate Immunity (2014) (23)
- Global antibody development trends (2009) (22)
- IBC’s 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society (2013) (20)
- IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of The Antibody Society (2011) (19)
- Probabilities of success for antibody therapeutics (2009) (17)
- 9th Annual European Antibody Congress, November 11–13, 2013, Geneva, Switzerland (2014) (16)
- IBC’s 22nd Annual Antibody Engineering and 9th Annual Antibody Therapeutics International Conferences and the 2011 Annual Meeting of The Antibody Society, December 5–8, 2011, San Diego, CA (2011) (15)
- Trends in the Development and Approval of Monoclonal Antibodies for Viral Infections (2012) (14)
- Technology evaluation: lumiliximab, Biogen Idec. (2004) (13)
- The amazing, multipurpose antibody (2011) (13)
- Therapeutic cancer vaccines on trial (2002) (13)
- Clinical development of therapeutic recombinant proteins. (2003) (11)
- Antibodies to watch in 2023 (2022) (11)
- Bispecific antibodies and ADCs (2011) (11)
- Clinical Development of Therapeutic Medicines: A Biopharmaceutical versus Pharmaceutical Product Comparison (2001) (11)
- Note of appreciation to reviewers (2017) (10)
- 5th European Antibody Congress 2009 (2010) (10)
- Poster Sessions (2012) (10)
- Biopharmaceuticals approved in the EU 1995-1999: a European Union-United States comparison. (2001) (9)
- Finding value in the U.S. Food and Drug Administration's Fast Track program. (2009) (9)
- A triumph for glyco-engineering (2012) (9)
- The Effects of the Prescription Drug User Fee Act and the Food and Drug Administration Modernization Act on the Development and Approval of Therapeutic Medicines (2001) (9)
- 7th Annual European Antibody Congress 2011 (2012) (9)
- Ankyrin-G Promotes Cyclic Nucleotide-Gated Channel Transport to Rod Photoreceptor Sensory Cilia (2009) (8)
- Therapeutic Antibodies ‐ from Past to Future (2014) (8)
- Handbook of Therapeutic Antibodies: Dübel/Handbook of Therapeutic Antibodies (2014) (7)
- Evolution of Antibody Therapeutics (2017) (7)
- Antibody Engineering & Therapeutics, The Annual Meeting of The Antibody Society (2014) (7)
- 4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland (2009) (6)
- A decade of the Fast Track programme (2008) (6)
- Antibody Engineering and Therapeutics (2013) (5)
- Muromonab‐CD3 (Orthoclone OKT®3) (2014) (5)
- Antibody engineering & therapeutics, the annual meeting of the antibody society December 7–10, 2015, San Diego, CA, USA (2016) (4)
- Foundation review : The future of antibodies as cancer drugs (2012) (4)
- Second international conference on accelerating biopharmaceutical development (2009) (4)
- Second International Conference on Accelerating Biopharmaceutical Development: March 9-12, 2009, Coronado, CA USA (2009) (4)
- Monoclonal antibodies as innovative anti-infective agents. (2005) (3)
- Antibody engineering and therapeutics conference (2014) (3)
- Letter from the Editor (2010) (3)
- Trends in the development of therapeutic anti-cytokine antibodies. (2004) (3)
- Americas Antibody Congress (2009) (3)
- Postprandial lipemic response in infants and children. (1950) (3)
- Book Review Pharmacopolitics: Drug Regulation in the United States and Germany (Studies in Social Medicine.) By Arthur A. Daemmrich. 203 pp. Chapel Hill, University of North Carolina Press, 2004. $34.95. 0-8078-2844-0 (2004) (2)
- Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11–15, 2016, San Diego, CA (2015) (2)
- Antibody Engineering and Therapeutics Conference (2013) (2)
- Editorial for PEDS special issue on antibodies. (2010) (2)
- 7th Cancer Scientific Forum of the Cancéropôle Lyon Auvergne Rhône-Alpes (2012) (2)
- Americas Antibody Congress: September 21-23, 2009, Washington, D.C. (2009) (1)
- Note of appreciation to reviewers (2013) (1)
- IBC’s 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society (2012) (1)
- Antibody Engineering & Therapeutics 2015: The Antibody Society's annual meeting December 7–10, 2015, San Diego, CA (2015) (1)
- Progress at mAbs (2010) (1)
- 45. Adalimumab (Humira (2014) (1)
- Letter from the Editor (2009) (1)
- Letter from the Editor (2009) (0)
- 2011 upcoming meetings (2011) (0)
- Note of appreciation to reviewers (2018) (0)
- Alemtuzumab (Lemtrada, MabCampath)1 (2014) (0)
- 2012–13 Upcoming meetings (2012) (0)
- Upcoming meetings (2007) (0)
- Letter from the editor. (2009) (0)
- 2010 upcoming meetings (2010) (0)
- mAbs’s communication networks (2012) (0)
- Note of appreciation to reviewers (2011) (0)
- 2012 upcoming meetings (2012) (0)
- Note of appreciation to reviewers (2015) (0)
- Innovative antibody research and development (R&D) is the vanguard of a variety of science, technology, and medical fields that require substantial investment of both time and money. (2009) (0)
- 2012 Upcoming Meetings (2012) (0)
- 7th cancer scientific forum of theCancéropôle Lyon Auvergne Rhône-Alpes: March 20-21, 2012, Lyon, France. (2012) (0)
- 2012 upcoming meetings (2012) (0)
- 2011 upcoming meetings (2011) (0)
- Medicinal biotechnology products: big problems or big opportunities? (2001) (0)
- Changes in regulations for approval of therapeutics (2010) (0)
- Upcoming Meetings (1995) (0)
- 2011 upcoming meetings (2011) (0)
- Total Syntheses of (+)‐Acutiphycin (Ia) and (+)‐trans‐20,21‐ Didehydroacutiphycin (Ib). (1996) (0)
- th Annual European Antibody Congress 2011 (2012) (0)
- TIDES Main Conference Featured Presentations Deal Trends in Nucleic Acid Based Therapeutics: A Look at Past Deals and Thoughts on the Future (2010) (0)
- TESTIMONIALS — EXECUTIVE EDITORIAL BOARD, INTERNATIONAL EDITORIAL ADVISORY BOARD (2015) (0)
- 2011 upcoming meetings (2011) (0)
- Anticorps médicaments (2019) (0)
- 2012 upcoming meetings (2012) (0)
- Letter from the editor (2009) (0)
- Letter from the Editor (2009) (0)
- Note of appreciation to reviewers (2016) (0)
- Letter from the Editor (2009) (0)
- Abciximab (Reopro®), Bevacizumab (Avastin®), Certolizumab Pegol (Cimzia®), Eculizumab (Soliris®), Natalizumab (Tysabri®) (2014) (0)
- 2010 upcoming meetings (2010) (0)
- Upcoming Meetings (1982) (0)
- Upcoming Meetings (2004) (0)
- Approved therapeutic antibodies and in vivo diagnostics (2014) (0)
- 2010 Upcoming meetings (2010) (0)
- SYNTHESIS OF NITRO- AND AMINO-SUBSTITUTED THIOBENZAMIDES BY THIOLATION REACTIONS WITH ELEMENTAL SULFUR UNDER MILD CONDITIONS (1978) (0)
- Golimumab (Simponi®)1 (2014) (0)
- Note of appreciation to reviewers (2010) (0)
- Antibody Therapeutics on the Horizon: An Overview of Bioengineered Formats in Clinical Studies (2014) (0)
- Letter from the Editor (2009) (0)
- 2011 upcoming meetings (2011) (0)
- 1 Therapeutic Antibodies – from Past to Future (2014) (0)
- Antibody therapeutics for COVID-19 (2020) (0)
- [Antibody therapeutics: an American view of an amazing present and future]. (2019) (0)
- Bispecific antibodies: a mechanistic review of the pipeline (2019) (0)
- 2011 upcoming meetings (2011) (0)
- Note of appreciation to reviewers (2012) (0)
- Upcoming meetings (2009) (0)
- Letter from the editor. (2009) (0)
- Upcoming Meetings (2009) (0)
- 2010 upcoming meetings (2010) (0)
- 2012 Upcoming Meetings (2012) (0)
- Note of appreciation to reviewers (2013) (0)
- Upcoming Meetings (2008) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Janice M. Reichert?
Janice M. Reichert is affiliated with the following schools:
